丙泊酚注射液在中国健康志愿者中的药动/药效学研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (11): 1249-1257.

丙泊酚注射液在中国健康志愿者中的药动/药效学研究

陈琳瑶¹, 周星辰², 郭歆², 苏桃², 程泽能¹

¹中南大学药学院生物药剂学及药物代谢动力学教研室,长沙 410013,湖南;
²湖南泰格湘雅药物研究有限公司,长沙 410013,湖南

收稿日期:2012-08-28 修回日期:2012-11-04 出版日期:2012-11-26 发布日期:2012-12-04
通讯作者: Protessor CHENG Ze-neng, male, doctorial tutor.Tel: 0731-82650451 E-mail: chengzenengcsu@yahoo.com.cn
作者简介:CHEN Lin-yao, female, graduate student, magor in drug metablism and pharmacokinetics.Tel: 0731-82650446 E-mail: cly89@126.com

Pharmacokinetics/pharmacodynamics evaluation of two injection formulations of propofol in Chinese healthy volunteers

CHEN Lin-yao¹, ZHOU Xing-chen², GUO Xin², SU Tao², CHENG Ze-neng

¹Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan,China; ²Hunan Tiger Xiangya R&D Co., Ltd, Changsha 410013,Hunan, China;

Received:2012-08-28 Revised:2012-11-04 Online:2012-11-26 Published:2012-12-04
Contact: Protessor CHENG Ze-neng, male, doctorial tutor.Tel: 0731-82650451 E-mail: chengzenengcsu@yahoo.com.cn
About author:CHEN Lin-yao, female, graduate student, magor in drug metablism and pharmacokinetics.Tel: 0731-82650446 E-mail: cly89@126.com

摘要/Abstract

摘要： 目的: 丙泊酚是临床上广泛使用的短效静脉麻醉药,本文通过研究丙泊酚的药动学和药效学特征,从而评价国产丙泊酚注射液与进口产品的治疗等效性。方法: 采用随机、双盲、两周期、交叉试验设计。共入组受试者24名,于不同周期分别给予试验制剂或对照药,周期间的洗脱期为 7 d。受试者在心电、脑电监护的情况下给药,给药前2 min至用药后 15 min 实时记录脑电双频指数(BIS值)、听觉诱发电位指数(AAI)、心率、呼吸、血压、血氧饱和度,记录麻醉时间。采用HPLC-Flu法测定血浆药物浓度。试验过程中记录不良事件。结果: 共23名受试者完成本试验,试验制剂与参比制剂的主要药动学参数如下: C_max 分别为 2.284 和 2.452 mg/L; t_max 分别为4 和 4 min; AUC_0-t 分别为 0.706 和 0.423 mg·h·L^-1; AUC_0-∞ 分别为 0.471 和 0.506 mg·h·L^-1。两制剂间的相对生物利用度为 93.1%。试验制剂与参比制剂的主要药效学参数如下:BIS_min分别为 51 and 53; AAI_min分别为18 和20; BISAUC_{0-15 min}分别为 373.4 和 342.7; AAIAUC_{0-15 min}分别为 892.5 和 850.5。结论: 国产丙泊酚注射液与进口产品在药动学及药效学均具有等效性,且安全性良好,故认为二者具治疗等效性。

关键词: 丙泊酚, 生物等效性, 药动学, 药效学, HPLC-Flu, 健康志愿者

Abstract: AIM: Propofol is a widely used intravenous anesthetic agent. Few pharmacokinetic (PK) and pharmacodynamic (PD) information of propofol is available in a Chinese population. The aim of the study is to evaluate PK and PD characteristics, assessing the therapeutic equivalence between two injection formulations of propofol in Chinese healthy volunteers. METHODS: Twenty-four healthy male volunteers were enrolled in a randomized, double-blinded, crossover study, receiving a 2 mg/kg bolus injection of test or reference formulation in two study arms. Plasma propofol concentration was determined by a validated HPLC-Flu method. PD parameters, Bispectral Index (BIS) and A-line ARX Index (AAI), were recorded by EEG monitor till 15 min postdose. In addition, times to onset of and emergence from hypnosis were observed. RESULTS: Twenty-three subjects accomplished the trial. The mean values of C_max, t_max, AUC_0-t, AUC_0-∞ of test and reference formulations were 2.284 and 2.452 mg/L; 4 and 4 min; 0.706 and 0.423 mg·h·L^-1; 0.471 and 0.506 mg·h·L^-1, respectively. The mean values of PD parameters of test and reference formulations were as follows: BIS_min, 51 and 53, respectively; AAI_min, 18 and 20; BISAUC_{0-15 min}, 373.4 and 342.7; AAIAUC_{0-15 min}, 892.5 and 850.5. The 90% CIs for the logarithmic transformations of C_max, AUC_0-t, AUC_0-∞, BISAUC_{0-15 min}, BIS_min, AAIAUC_{0-15 min}, AAI_min(0.795-0.999, 0.838-0.985, 0.861-0.989, 1.023-1.151, 0.865-1.025, 0.999-1.099, 0.826-1.008, respectively) were within the bioequivalence acceptance limits. No serious adverse events occurred in the trial.CONCLUSION: Results indicated that no significant difference was found between test and reference formulations of propofol in the aspects of pharmacokinetic and pharmacodynamic. Both formulations were well tolerated. Therefore, we believe that the two injection formulations of propofol are therapeutic equivalence in Chinese healthy volunteers.

Key words: Propofol, Therapeutic equivalence, Pharmacokinetics, Pharmacodynamics, HPLC-Flu, Healthy volunteer

中图分类号:

R969.1

陈琳瑶, 周星辰, 郭歆, 苏桃, 程泽能. 丙泊酚注射液在中国健康志愿者中的药动/药效学研究[J]. 中国临床药理学与治疗学, 2012, 17(11): 1249-1257.

CHEN Lin-yao, ZHOU Xing-chen, GUO Xin, SU Tao, CHENG Ze-neng. Pharmacokinetics/pharmacodynamics evaluation of two injection formulations of propofol in Chinese healthy volunteers[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1249-1257.

参考文献

[1] Bryson HM, Fulton BR, Faulds D.Propofol: an update of its use in anaesthesia and conscious sedation[J]. Drugs,1995,50(3):513-559.
[2] Fulton B, Sorkin EM.Propofol: an overview of its pharmacology and a review of its clinical efficacy in intensive care sedation[J]. Drugs,1995,50(3):636-657.
[3] Schüttler J, Ihmsen H.Population pharmacokinetics of propofol: a multicenter study[J]. Anesthesiology, 2000,92(3): 727-738.
[4] Kataria BK, Ved SA, Nicodemus HF,et al.The pharmacokinetics of propofol in children using three different data analysis approaches[J]. Anesthesiology, 1994,80(1):104-122.
[5] Campbell GA, Morgan DJ, Kumar K, et al.Extended blood collection period required to define distribution and elimination kinetics of propofol[J]. Br J Clin Pharmacol, 1988,26(2): 187-190.
[6] Borgeat A, Stirnemann HR.Antiemetic effect of propofol[J]. Anaesthesist, 1998,47(11): 918-924.
[7] Soppitt AJ, Glass PS, Howell S, et al.The use of propofol for its antiemetic effect: a survey of clinical practice in the United States[J].J Clin Anesth, 2000, 12(4): 265-269.
[8] DeBalli P. The use of propofol as an antiemetic[J]. Int Anesthesiol Clin, 2003, 41(4): 67-77.
[9] European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on the Investigation of Bioavailability and Bioequivalence[J].London: EMEA, 2001.
[10] Knibbe CA, Voortman HJ, Aarts LP, et al.Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection[J].Br J Clin Pharmacol, 1999,47(6):653-660.
[11] Abad-Santos F, Gálvez-Múgica MA, Santos MA, et al.Pharmacokinetics and Pharmacodynamics of a Single Bolus of Propofol 2% in Healthy Volunteers[J]. J Clin Pharmacol, 2003,43(4): 397-405.
[12] LIU Jing,MI Wei-dong,ZHANG Hong.Auditory evoked potential index and bispectral index in predicting body movement during propofol anesthesia[J].Chinese Journal of Anesthesiolog,2006,26(11):983-985.
[13] Song CY, Xi HJ, Yang L, et al.Propofol inhibited the delayed rectifier potassium current I( k) via activation of protein kinaseC epsilon in rat parietal cortical neurons[J]. Eur J Pharmacol, 2011,653(1/2/3): 16-20.
[14] Wang L, Wu B, Sun Y, et al.Translocation of protein kinase Cisoforms is involved in propofol-induced endothelial nitric oxide synthase activation[J]. Br J Anaesth, 2010, 104(5): 606-612.
[15] Haines M, Mao LM, Yang L, et al.Modulation of AMPA receptor GluR1 subunit phosphorylation in neurons by the intravenous anaesthetic propofol[J]. Br J Anaesth, 2008, 100(5): 676-682.